Literature DB >> 24419081

AAV9-mediated expression of a non-self protein in nonhuman primate central nervous system triggers widespread neuroinflammation driven by antigen-presenting cell transduction.

Lluis Samaranch1, Waldy San Sebastian1, Adrian P Kells1, Ernesto A Salegio2, Gregory Heller1, John R Bringas1, Philip Pivirotto1, Stephen DeArmond3, John Forsayeth1, Krystof S Bankiewicz4.   

Abstract

Many studies have demonstrated that adeno-associated virus serotype 9 (AAV9) transduces astrocytes and neurons when infused into rat or nonhuman primate (NHP) brain. We previously showed in rats that transduction of antigen-presenting cells (APC) by AAV9 encoding a foreign protein triggered a full neurotoxic immune response. Accordingly, we asked whether this phenomenon occurred in NHP. We performed parenchymal or intrathecal infusion of AAV9 encoding green fluorescent protein (GFP), a non-self protein derived from jellyfish, or human aromatic L-amino acid decarboxylase (hAADC), a self-protein, in separate NHP. Animals receiving AAV9-GFP into cisterna magna (CM) became ataxic, indicating cerebellar pathology, whereas AAV9-hAADC animals remained healthy. In transduced regions, AAV9-GFP elicited inflammation associated with early activation of astrocytic and microglial cells, along with upregulation of major histocompatibility complex class II (MHC-II) in glia. In addition, we found Purkinje neurons lacking calbindin after AAV9-GFP but not after AAV9-hAADC delivery. Our results demonstrate that AAV9-mediated expression of a foreign-protein, but not self-recognized protein, triggers complete immune responses in NHP regardless of the route of administration. Our results warrant caution when contemplating use of serotypes that can transduce APC if the transgene is not syngeneic with the host. This finding has the potential to complicate preclinical toxicology studies in which such vectors encoding human cDNA's are tested in animals.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24419081      PMCID: PMC3918916          DOI: 10.1038/mt.2013.266

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  26 in total

1.  Efficient neuronal gene transfer with AAV8 leads to neurotoxic levels of tau or green fluorescent proteins.

Authors:  Ronald L Klein; Robert D Dayton; Nancy J Leidenheimer; Karen Jansen; Todd E Golde; Richard M Zweig
Journal:  Mol Ther       Date:  2005-12-01       Impact factor: 11.454

2.  Gene transfer to the CNS is efficacious in immune-primed mice harboring physiologically relevant titers of anti-AAV antibodies.

Authors:  Christopher M Treleaven; Thomas J Tamsett; Jie Bu; Jonathan A Fidler; S Pablo Sardi; Gregory D Hurlbut; Lisa A Woodworth; Seng H Cheng; Marco A Passini; Lamya S Shihabuddin; James C Dodge
Journal:  Mol Ther       Date:  2012-06-26       Impact factor: 11.454

3.  Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach.

Authors:  K S Bankiewicz; J L Eberling; M Kohutnicka; W Jagust; P Pivirotto; J Bringas; J Cunningham; T F Budinger; J Harvey-White
Journal:  Exp Neurol       Date:  2000-07       Impact factor: 5.330

4.  Convection-enhanced delivery of macromolecules in the brain.

Authors:  R H Bobo; D W Laske; A Akbasak; P F Morrison; R L Dedrick; E H Oldfield
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

5.  A dose-ranging study of AAV-hAADC therapy in Parkinsonian monkeys.

Authors:  John R Forsayeth; Jamie L Eberling; Laura M Sanftner; Zhu Zhen; Philip Pivirotto; John Bringas; Janet Cunningham; Krystof S Bankiewicz
Journal:  Mol Ther       Date:  2006-06-16       Impact factor: 11.454

6.  Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors.

Authors:  Steven J Gray; Stacey B Foti; Joel W Schwartz; Lavanya Bachaboina; Bonnie Taylor-Blake; Jennifer Coleman; Michael D Ehlers; Mark J Zylka; Thomas J McCown; R Jude Samulski
Journal:  Hum Gene Ther       Date:  2011-06-01       Impact factor: 5.695

7.  Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy.

Authors:  Virginia Haurigot; Sara Marcó; Albert Ribera; Miguel Garcia; Albert Ruzo; Pilar Villacampa; Eduard Ayuso; Sònia Añor; Anna Andaluz; Mercedes Pineda; Gemma García-Fructuoso; Maria Molas; Luca Maggioni; Sergio Muñoz; Sandra Motas; Jesús Ruberte; Federico Mingozzi; Martí Pumarola; Fatima Bosch
Journal:  J Clin Invest       Date:  2013-07-01       Impact factor: 14.808

8.  Cerebral infusion of AAV9 vector-encoding non-self proteins can elicit cell-mediated immune responses.

Authors:  Agnieszka Ciesielska; Piotr Hadaczek; Gabriele Mittermeyer; Shangzhen Zhou; J Fraser Wright; Krystof S Bankiewicz; John Forsayeth
Journal:  Mol Ther       Date:  2012-08-28       Impact factor: 11.454

9.  Advancements in adeno-associated viral gene therapy approaches: exploring a new horizon.

Authors:  Caroline J Aalbers; Paul P Tak; Margriet J Vervoordeldonk
Journal:  F1000 Med Rep       Date:  2011-09-01

10.  Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders.

Authors:  Adam K Bevan; Sandra Duque; Kevin D Foust; Pablo R Morales; Lyndsey Braun; Leah Schmelzer; Curtis M Chan; Mary McCrate; Louis G Chicoine; Brian D Coley; Paul N Porensky; Stephen J Kolb; Jerry R Mendell; Arthur H M Burghes; Brian K Kaspar
Journal:  Mol Ther       Date:  2011-08-02       Impact factor: 11.454

View more
  69 in total

1.  Cerebellomedullary Cistern Delivery for AAV-Based Gene Therapy: A Technical Note for Nonhuman Primates.

Authors:  Lluis Samaranch; John Bringas; Philip Pivirotto; Waldy San Sebastian; John Forsayeth; Krystof Bankiewicz
Journal:  Hum Gene Ther Methods       Date:  2016-02       Impact factor: 2.396

Review 2.  Viral vectors for therapy of neurologic diseases.

Authors:  Sourav R Choudhury; Eloise Hudry; Casey A Maguire; Miguel Sena-Esteves; Xandra O Breakefield; Paola Grandi
Journal:  Neuropharmacology       Date:  2016-02-21       Impact factor: 5.250

3.  Transduction of antigen-presenting cells in the brain by AAV9 warrants caution in preclinical studies.

Authors:  John Forsayeth; Krystof S Bankiewicz
Journal:  Mol Ther       Date:  2015-04       Impact factor: 11.454

4.  Nonhuman Primate Optogenetics: Current Status and Future Prospects.

Authors:  Ken-Ichi Inoue; Masayuki Matsumoto; Masahiko Takada
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Extensive Transduction and Enhanced Spread of a Modified AAV2 Capsid in the Non-human Primate CNS.

Authors:  Jerusha Naidoo; Lisa M Stanek; Kousaku Ohno; Savanah Trewman; Lluis Samaranch; Piotr Hadaczek; Catherine O'Riordan; Jennifer Sullivan; Waldy San Sebastian; John R Bringas; Christopher Snieckus; Amin Mahmoodi; Amir Mahmoodi; John Forsayeth; Krystof S Bankiewicz; Lamya S Shihabuddin
Journal:  Mol Ther       Date:  2018-07-12       Impact factor: 11.454

Review 6.  Gene therapy for neurological disorders: progress and prospects.

Authors:  Benjamin E Deverman; Bernard M Ravina; Krystof S Bankiewicz; Steven M Paul; Dinah W Y Sah
Journal:  Nat Rev Drug Discov       Date:  2018-08-10       Impact factor: 84.694

7.  Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders.

Authors:  K Bey; C Ciron; L Dubreil; J Deniaud; M Ledevin; J Cristini; V Blouin; P Aubourg; M-A Colle
Journal:  Gene Ther       Date:  2017-04-20       Impact factor: 5.250

Review 8.  Comparison of high-dose intracisterna magna and lumbar puncture intrathecal delivery of AAV9 in mice to treat neuropathies.

Authors:  Rachel M Bailey; Alejandra Rozenberg; Steven J Gray
Journal:  Brain Res       Date:  2020-04-11       Impact factor: 3.252

9.  Broad distribution of ataxin 1 silencing in rhesus cerebella for spinocerebellar ataxia type 1 therapy.

Authors:  Megan S Keiser; Jeffrey H Kordower; Pedro Gonzalez-Alegre; Beverly L Davidson
Journal:  Brain       Date:  2015-10-21       Impact factor: 13.501

10.  Progranulin Gene Therapy Improves Lysosomal Dysfunction and Microglial Pathology Associated with Frontotemporal Dementia and Neuronal Ceroid Lipofuscinosis.

Authors:  Andrew E Arrant; Vincent C Onyilo; Daniel E Unger; Erik D Roberson
Journal:  J Neurosci       Date:  2018-01-29       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.